$TNXP 12-07-2020 Tonix Pharmaceuticals is enrolling participants in a
Phase 3 trial for fibromyalgia, the RALLY study.
For more information, please visit
http://www.RALLYStudy.com or
http://www.clinicaltrials.gov (NCT04508621).
https://www.tonixpharma.com/ Latest News
Tonix Pharmaceuticals Announces Positive Phase 3 RELIEF Study Results for TNX-102 SL 5.6 mg in Fibromyalgia • December 7, 2020 • 7:00 AM EST
06-20-2020 T-CELL THEORY INSIDE T-CELL KILLS VIRUS FROM WITHIN !!!!!
$TNXP DIRECTORS, ONTRACK FOR T-CELLS. I WAS WATCHING FOX T.V. AND T-CELLS ATTACK VIRUS FROM WITHIN NOT OUTSIDE OF CELLS. Plan to Produce Blueprint of How the Human Immune System Responds to Infection Caused by SAR-CoV-2, the Virus that Causes COVID-19 Results Expected to Support Tonix’s Anticipated Regulatory Filings for TNX-1800, a Live Replicating Virus Vaccine Designed to Elicit T Cell Immunity in Addition to Antibodies THIS COULD BE HUGE HERE FOR THIS PLATFORM !!!!! https://finance.yahoo.com/news/tonix-pharmaceuticals-southern-research-announce-110010137.html $NK DOES THIS ONLY ONE DOING VIRUS FROM INSIDE T-CELL PER Interview with Dr. Patrick Soon-Shiong 06-20-2020
NEW YORK, June 18, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP) (Tonix or the Company),
a clinical-stage biopharmaceutical company, announced today an expansion of its strategic collaboration with Southern Research to include a study of
T cell immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19.
The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix’s TNX-1800,
which is a live replicating virus vaccine designed to protect against COVID-19. The data will support the interpretation of animal trial results with TNX-1800,
which are expected in the fourth quarter of 2020 and subsequent human trials.
“More than 200 years of vaccine experience, beginning with Dr. Edward Jenner’s landmark discoveries with horsepox and cowpox vaccines, have shown that
T cell eliciting vaccines are particularly effective against viruses,” said Seth Lederman, M.D., President and CEO of Tonix.
“We believe that protective vaccines against the SARS-CoV-2 virus will be similar in that regard.
The data we plan to collect from recovered and asymptomatic COVID-19 volunteers will inform vaccine development on how to safely
provide to vaccine recipients the same immune responses that others got from recovering from actual CoV-2 infection.
If approved by the U.S. Food and Drug Administration (FDA) for use in healthy, non-pregnant adults without moderate or severe eczema,
TNX-1800 would feature single-dose immunity without the use of adjuvants, ease of manufacturing on readily available systems,
and glass-sparing distribution since we believe 100 doses of TNX-1800 could be packaged in a single vial.
Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed.”
ON FOX T.V.MARIA INTERVIEW CEO OF $ NK---Soon-Shiong is also the CEO of the Nantworks
NantKwest (NK)
Dr. Patrick-Soon-Shiong Wikipedia Bio
Forbes Profile Patrick Soon-Shiong
Excellent Interview Larry King Live
$TNXP; Financials=As of May 11, 2020, the Company has an aggregate of 52,302,475 shares of common stock outstanding. $TNXP
As of March 31, 2020, the Company had cash and cash equivalents of $30.7 million, compared to $11.2 million at December 31, 2019.
The Company had no debt outstanding at March 31, 2020. Debt/Eq 0.00-LT Debt/Eq 0.00, Employees 16
Book/sh 1.52, 52W Range 0.39 - 24.90, SELLING 1/2 X'S BOOK.
[BUYER] Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4 LEDERMAN SETH Chief Executive Officer Dec 03 Buy 1.16 20,000 23,180 23,267 Dec 04 07:00 AM https://finviz.com/quote.ashx?t=TNXP
Attractive Product with $650 Million Potential ! Tonix Pharmaceuticals Holding Corp (TNXP)
HUGE NEWS!
Tonix Pharmaceuticals Announces Research Collaboration with Southern Research to Develop a Potential Vaccine to Protect Against New Coronavirus Disease 2019 (COVID-19) Based on Horsepox Virus (TNX-1800)
TNXP Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX...
| Stockholders' equity: | | |
Preferred stock:
5,000,000 shares authorized Series A Convertible Preferred stock, 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
| | |
Common stock:
150,000,000 shares authorized;
6,338,320 and 3,251,970 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively, and 23,792 and 1,758 shares to be issued as of June 30, 2019 and December 31, 2018, respectively
Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-005974/0001387131-19-005974.pdf
On October 31, 2019, the Company filed a Certificate of Change with the Nevada Secretary of State, which was effective November 1, 2019. Pursuant to the Certificate of Change, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 15,717,402 outstanding shares of the Company’s common stock were exchanged for 1,575,246 shares of the Company’s common stock. In connection with the reverse stock split, the Company issued an additional 3,457 shares of the Company’s common stock due to rounding. Furthermore, pursuant to the Certificate of Change, the number of authorized shares of common stock was reduced from 150 million to 15 million. All per share amounts and number of shares in the condensed consolidated financial statements and related notes have been retroactively restated to reflect the reverse stock split.
Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-008474/0001387131-19-008474.pdf
| | |
Financials
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands | June 30, 2019 | Dec. 31, 2018 |
| Current assets: | | |
| Cash and cash equivalents | $ 12,150 | $ 25,034
|
Website
https://www.tonixpharma.com 
http://www.amazonaws.com
Summary
Phase 3 development of new bedtime treatment for PTSD, including militaryrelated PTSD
• Major unmet need; ~12 million Americans annually
• Benefited from FDA 505(b)(2) NDA approval requirement
Complimentary day-time PTSD treatment in development
• Leverages development expertise in PTSD, i.e., regulatory, trial recruitment and execution
Fibromyalgia bedtime treatment in development
• New Phase 3 study design features discussed with FDA (April 2019 FDA Meeting Minutes)
• TNX-102 SL 5.6 mg (twice the dose previously studied in FM Phase 2/3 trials) will be studied in Phase 3 to support the indication
New indication in development for agitation in Alzheimer’s Disease
• Unmet medical need, no approved drug available
• Fast Track Phase 2/3 ready program
Innovative vaccine in development to prevent Smallpox
• Opportunity to supply stockpiling requirement; short development path
• Studies in mice suggest improved safety profile Conclusion and Valuation
The U.S. military’s intense interest in identifying safe and effective PTSD treatments is important for Tonix, as the AtEase study is the only controlled clinical trial to show a benefit in treating military related PTSD. If those results can be duplicated in the HONOR study (and Tonmya® gets approved), the Department of Defense and the VA would likely be very interested in getting the treatment to military personnel and veterans who suffer from PTSD.
Our valuation for Tonix is derived from a probability adjusted discounted cash flow model that takes into account potential future revenues from the sale of TNX-102 SL in PTSD. Of the approximately 8.6 million individuals in the U.S. who suffer from PTSD, it’s estimated that approximately 20% seek treatment. With a peak market share of only 6%, we currently estimate that peak sales of $650 million are possible. Using a discount rate of 18% and a 50% probability of approval leads to a net present value for the PTSD program of $67 million. Combined with the company’s current cash position and dividing by a reasonable fully diluted share count of 8.1 million shares leads to a valuation of approximately $13 per share.
Insider & Institutional Ownership :
Rosalind Advisors, Inc. 553 908
Baker Bros. Advisors LP 510 922
B. Riley Capital Management LLC 378 138
Opaleye Management, Inc. 370 000
Empery Asset Management LP 315 000
The Vanguard Group, Inc. 184 377
Heights Capital Management, Inc. 89 713
Seth Lederman, MD 83 400
Ernest Mario, PhD 69 718
Kingdon Capital Management LLC 64 549
-----------------------
IR Contact Information
Transfer Agent
vStock Transfer
77 Spruce Street
Suite 201
Cedarhurst, NY 11516
T: 212-828-8436
www.vstocktransfer.com
--------------------------- If you guys want that the stock moving even faster then put your shares on high GTC sell order like $10
this helps to prevent your shares from being shorted and more important your shares wouldnt be available
on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news.
This works good especially on stocks like TNXP which has only 10 million shares outstanding.
Thank you
How to Prevent your Shares Holdings from being Shorted http://www.contracts-for-difference.com/Borrowing-lending-shares.html ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
PARTNER
LINKS, https://southernresearch.org/drug-development/ https://southernresearch.org/drug-discovery/ https://southernresearch.org/engineering/ https://southernresearch.org/eande/ https://southernresearch.org/medtech/ https://southernresearch.org/stem/ https://southernresearch.org/events/ https://southernresearch.org/newsletter/ https://southernresearch.org/magazine/ https://southernresearch.org/news/category/cancer-research/ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
2,$TNXP,from website. Southern Research, Tonix team to develop potential vaccine against new coronavirus
FEBRUARY 26, 2020 | BY JERRY UNDERWOOD | DRUG DEVELOPMENT
Southern Research announced today that it has entered into a strategic collaboration with New York-based Tonix Pharmaceuticals Holding Corp.,
a clinical-stage biopharmaceutical company, to support the development of a vaccine, […]
https://southernresearch.org/drug-development/
TONIX PHARMACEUTICALS HOLDING CORP. 8-K
https://www.sec.gov/Archives/edgar/data/1430306/000138713120003042/ex99-1.htm 
https://finviz.com/quote.ashx?t=tnxp&ty=c&ta=1&p=d 
https://www.otcmarkets.com/stock/TNXP/disclosure https://www.otcmarkets.com/stock/TNXP/news https://www.otcmarkets.com/stock/TNXP/security Market Cap Market Cap 100,072,086 Authorized Shares..400,000,000 Outstanding Shares168,585,050 https://www.otcmarkets.com/stock/TNXP/profile https://www.otcmarkets.com/stock/TNXP/quote https://www.otcmarkets.com/stock/TNXP/overview DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.